Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest

Main Article Content

Kristian Reich
Eric Simpson
Richard Langley
Richard Warren
Antonio Costanzo
Hidehisa Saeki
Peter Almgren
Le Gjerum
Anna Carlsson
Melinda Gooderham
Andreas Pinter
Marjolein De Bruin Weller
Andrew Blauvelt


atopic dermatitis, tralokinumab


1. Nutten S. Ann Nutr Metab. 2015;66(Suppl1):8-16.

2. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

3. Popovic B, et al. J Mol Biol. 2017;429:208-19.

4. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449.

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463.

6. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>